Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease-Reference-Cited by-同舟云学术

Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease

Published:2021-10-19 Issue:16 Volume:144 Page:1323-1343
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Calabrò Paolo¹²^ORCID,Gragnano Felice¹²,Niccoli Giampaolo³⁴⁵,Marcucci Rossella⁶,Zimarino Marco⁷^ORCID,Spaccarotella Carmen⁸,Renda Giulia⁷,Patti Giuseppe⁹^ORCID,Andò Giuseppe¹⁰^ORCID,Moscarella Elisabetta¹²,Mancone Massimo¹¹,Cesaro Arturo¹²,Giustino Gennaro¹²,De Caterina Raffaele¹³^ORCID,Mehran Roxana¹²^ORCID,Capodanno Davide¹⁴¹⁵^ORCID,Valgimigli Marco¹⁶¹⁷^ORCID,Windecker Stephan¹⁷^ORCID,Dangas George D.¹²,Indolfi Ciro⁸¹⁸,Angiolillo Dominick J.¹⁹^ORCID,

Affiliation:

1. Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli,” Naples, Italy (P.C., F.G., E.M., A.C.).

2. Division of Cardiology, A.O.R.N. “Sant’Anna e San Sebastiano,” Caserta, Italy (P.C., F.G., E.M., A.C.).

3. Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy (G.N.).

4. Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy (G.N.).

5. Department of Medicine, University of Parma, Italy (G.N.).

6. Department of Experimental and Clinical Medicine, University of Florence, Italy (R. Marcucci.).

7. Institute of Cardiology, University “G. D’Annuzio” of Chieti-Pescara, Italy (M.Z., G.R).

8. Department of Medical and Surgical Sciences, Magna Grecia University, Catanzaro, Italy (C.S., C.I.).

9. Department of Translational Medicine, “Maggiore della Carità” Hospital, University of Eastern Piedmont, Via Solaroli, Novara, Italy (G.P.).

10. Unit of Cardiology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy (G.A.).

11. Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy (M.M.).

12. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York (G.G., R. Mehran., G.D.D.).

13. University Cardiology Division, University of Pisa, Pisa University Hospital, Italy; Fondazione Villa Serena per la Ricerca, Città Sant’Angelo, Italy (R.D.C.).

14. Cardio-Thoracic-Vascular Department, Centro Alte Specialità e Trapianti, Catania, Italy (D.C.).

15. Azienda Ospedaliero Universitaria Policlinico “G. Rodolico-San Marco,” University of Catania, Italy (D.C.).

16. Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Lugano, Switzerland (M.V.).

17. Department of Cardiology, Bern University Hospital, University of Bern, Switzerland (M.V., S.W.).

18. Mediterranea Cardiocentro, Naples, Italy (C.I.).

19. Division of Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).

Abstract

Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Link

https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.121.054305

Reference100 articles.

1. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

2. 2017 ESC/EACTS Guidelines for the management of valvular heart disease

3. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

4. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

5. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High Bleeding Risk in Patients Undergoing Coronary and Structural Heart Interventions;Interventional Cardiology Clinics;2024-10

2. Favorable safety profile of NOAC therapy in patients after tricuspid transcatheter edge-to-edge repair;Clinical Research in Cardiology;2024-08-19

3. Early and late hospital readmissions after percutaneous left atrial appendage closure;Revista Española de Cardiología (English Edition);2024-08

4. Authoring, reviewing and perusing: the cardiovascular scholarly continuum;Minerva Cardiology and Angiology;2024-05

5. Percutaneous Tricuspid Valve Repair: The Triclip;Cardiology in Review;2024-04-26